
Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein

Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein		
Cat. No. HLG-H	M41CT	
Description		
Source	Recombinant Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus,tetramer is assembled by biotinylated monomer and streptavidin.	
	It contains Gly25-Thr305(HLA-G), Ile21-Met119(B2M) and RIIPRHLQL peptide.	
Accession	P17693-1(HLA-G)&P61769(B2M)&RIIPRHLQL	
Molecular Weight	The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.	
Endotoxin	Less than 1EU per µg by the LAL method.	
Purity	> 95% as determined by Tris-Bis PAGE	
	> 90% as determined by HPLC	
Formulation and	Storage	
Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.	
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.	
Storage	-20 to -80°C for 12 months as supplied from date of receipt80°C for 7 days after reconstitution. Recommend to aliquot the protein into sma minimize freeze-thaw cycles.	
Background		
	HLA-G is a molecule that was first known to confer protection to the fe of its mother, thus critically contributing to fetal-maternal tolerance. Th basis for HLA-G research and can be summarized as such: HLA-G, m its inhibitory receptors on immune cells (NK, T, B, monocytes/dendritic effectors, and so induces immune inhibition.	e first functional finding constituted the nembrane-bound or soluble, strongly binds

Assay Data



Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer on Tris-Bis PAGE under Non reducing (N) condition. The purity is greater than 95%.


SEC-HPLC

Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein

Cat. No. HLG-HM41CT

Assay Data





The purity of Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer is greater than 90% as determined by SEC-HPLC.

Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein


Cat. No. HLG-HM41CT

Assay Data

ELISA Data

Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His Tag ELISA

0.05µg Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His Tag Per Well




Immobilized Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His Tag at 0.5µg/ml (100µl/well) on the plate. Dose response curve for Anti-HLA-G Antibody, hFc Tag with the EC50 of 6.2ng/ml determined by ELISA (QC Test).


ᠺ᠕ᡗ᠋ᠴᡃ᠐ᠫ

Blocking Data






SPR Data



Human LILRB2, hFc Tag captured on CM5 Chip via Protein A can bind Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer with an affinity constant of 4.62 nM as determined in SPR assay (Biacore T200).

SPR Data



Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His Tag immobilized on CM5 Chip can bind Human LILRB2 Domain1&2, His Tag with an affinity constant of 6.5μ M as determined in a SPR assay (Biacore T200).

Serial dilutions of Anti-LILRB2 Antibody were added into Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His Tag : Human LILRB2, mFc Tag binding reactioins. The half maximal inhibitiory concentration (IC50) is 0.11µg/ml.

For Research Use Only